Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16029956 | 0.80 | MAPT (0.38) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL16029651 | 0.80 | MAPT (0.45) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL16029633 | 0.80 | MAPT (0.38) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL680567 | 0.76 | MAPT (0.38) | MAPTGAAKMT2AMEN1HSD17B10 | |
| SCHEMBL6198782 | 0.70 | LMNA (0.37) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL28520045 | 0.67 | ADRA2A (0.52) | MAPTKMT2AALDH1A1MEN1USP2 | |
| SCHEMBL16029823 | 0.67 | MAPT (0.36) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL15572268 | 0.65 | NQO2 (0.44) | MAPTKMT2AALDH1A1MEN1CASP1 | |
| SCHEMBL9533749 | 0.65 | MAPT (0.58) | MAPTGAAKMT2AALDH1A1MEN1 | |
| SCHEMBL3192399 | 0.65 | MAPT (0.46) | MAPTGAAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105350-A | Luminous organic material and preparation method thereof, organic luminescent device | 武汉华星光电半导体显示技术有限公司 | 2019-08-09 | — | — | CN | disclosed |
| EP-3110812-B1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9938249-B2 | Anti-amyloid compounds containing benzofurazan | TREVENTIS CORPORATION (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | TREVENTIS CORPORATION (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2888252-B1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORP (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-3110812-A2 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | Treventis Corporation (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160264535-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2016-09-15 | — | — | US | disclosed |
| US-9328078-B2 | Benzofurazan anti-amyloid compounds and methods | TREVENTIS CORPORATION (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150266838-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION | 2015-09-24 | — | — | US | disclosed |
| EP-2888252-A2 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | Treventis Corporation (US) | 2015-07-01 | — | — | EP | disclosed |
| WO-2015030685-A1 | FLUORESCENT POLYMER DOTS, METHODS FOR THEIR PREPERATION, AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-05 | — | — | WO | disclosed |
| WO-2014031873-A2 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | TREVENTIS CORPORATION (US) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266838-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | PRNP, TTR, PSEN1 | MAPT 24/4885GAA 894/4885KMT2A 3905/4885 |
| US-20170174641-A1 | ANTI-AMYLOID COMPOUNDS CONTAINING BENZOFURAZAN | PRNP, PSEN1, APP | MAPT 14/4885GAA 322/4885KMT2A 2709/4885 |
| US-20160264535-A1 | BENZOFURAZAN ANTI-AMYLOID COMPOUNDS AND METHODS | PRNP, TTR, PSEN1 | MAPT 24/4885GAA 894/4885KMT2A 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.